Nimbus Therapeutics
Boston, Massachusetts, United States · Biotechnology, Health Care, Pharmaceutical
Nimbus Therapeutics, LLC is a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine.
Key facts
- Headquarters
- Boston, Massachusetts, United States
- Employees
- 105
- Industries
- Biotechnology, Health Care, Pharmaceutical
- Status
- Private
- Website
- nimbustx.com
- Company page
Recent activity at Nimbus Therapeutics
- : Nimbus Therapeutics and Eli Lilly Collaborate on Research for Obesity Treatment
- : Nimbus Therapeutics appoints Peter J. Tummino, Ph.D. as President of Research and Development
- : Nimbus Therapeutics Announces Positive Updated Data from Clinical Trial of HPK1 Inhibitor NDI-101150 for Advanced Solid Tumors
- : Nimbus Therapeutics Secures $210M Private Financing To Advance Next Wave Of Tech-Enabled Small Molecule Medicines
- : Nimbus Therapeutics Announces $105 Million Private Financing To Advance Pipeline Including Multiple Clinical Programs
Nimbus Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2023 | Funding Round | $210.0M |
| Jul 2021 | Funding Round | $105.0M |
Leadership
- Peter J. Tummino, President
- Erin Cowhig, Chief People Officer
- Jeb Keiper, Chief Executive Officer
Verified email and direct lines for Nimbus Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Nimbus Therapeutics in the news
- Nimbus Therapeutics, Eli Lilly Partner to Develop Novel Oral Metabolic Drug - The American Journal of Managed Care (Jan 06, 2026)
- Nimbus Therapeutics and Eli Lilly Enter $1.3 Billion License Agreement and Research Collaboration for Oral Obesity Treatments - Pharmaceutical Executive (Jan 06, 2026)
- Nimbus Therapeutics Strengthens Leadership Team to Support Next Phase of Growth - Business Wire (Oct 13, 2026)
- Nimbus’ Phase 1/2 Trial for NDI-101150 Shows Promise in Treating Advanced Solid Tumors - Applied Clinical Trials Online (May 24, 2024)
- Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors - FinancialContent (Mar 12, 2024)
- Nimbus Therapeutics Presents New Mechanistic Data Highlighting Differentiated Biology of Selective SIK2 Inhibitors at IMMUNOLOGY2026™ - Business Wire (Apr 16, 2026)
- Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors - Business Wire (Dec 19, 2025)
- Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment - Business Wire (Jan 06, 2026)
Companies similar to Nimbus Therapeutics
- Juvisé Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- 89bio · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Tanner Pharma · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Journey Therapeutics · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc · Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Nimbus Therapeutics: questions and answers
What does Nimbus Therapeutics do?
Nimbus Therapeutics, LLC is a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine.
Where is Nimbus Therapeutics headquartered?
Nimbus Therapeutics is headquartered in Boston, Massachusetts, United States.
How many employees does Nimbus Therapeutics have?
Nimbus Therapeutics has about 105 employees.
Has Nimbus Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for Nimbus Therapeutics. The most recent, Funding Round of $210.0M, was in Sep 2023.
Who leads Nimbus Therapeutics?
Peter J. Tummino is a President at Nimbus Therapeutics.
What is the latest news on Nimbus Therapeutics?
On Jan 06, 2026, Nimbus Therapeutics and Eli Lilly Collaborate on Research for Obesity Treatment
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy